Overview


According to FutureWise analysis the market for human microbiome therapeutics in 2023 is US$ 0.63 billion, and is expected to reach US$ 3.5 billion by 2031 at a CAGR of 23.92%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Microbiome Therapeutics Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Human Microbiome Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Bristol-Myers Squibb Co.
  • Dow Inc.
  • ENTEROME SA
  • Ferring Pharmaceuticals AS
  • Johnson and Johnson
  • Kaleido Biosciences Inc.
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Vedanta Biosciences
  • Whole Biome
  • Naked Biome
  • Evelo Biosciences
  • LNC Therapeutics
  • Biotagenics
  • Oxidien Pharmaceuticals, LLC
  • BoobyBiome
  • 4D Pharma PLC
  • UBiome
  • Carbiotix
  • E.I. du Pont de Nemours and Company
  • Finch Therapeutics
  • GNUbiotics Sciences
  • ClearB Therapeutics
  • GoodBelly
  • GoodGut
  • Synlogic
  • 16S Technologies
  • 5QBD-Biotech

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Probiotics
  • Prebiotics
  • Medical Foods
  • Prescription Drugs

By Therapeutic Area

  • Autoimmune Disorders
  • Dental Disorders
  • Digestive and Gastrointestinal Disorders
  • Dermatological Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Others

By Indication

  • Acne Vulgaris
  • Atopic Dermatitis
  • Clostridium difficile Infection
  • Colorectal Cancer
  • Diabetes
  • Inflammatory Bowel Disease (IBD)
  • Lactose Intolerance
  • Lung Cancer
  • Non-alcoholic steatohepatitis (NASH)
  • Obesity
  • Coeliac Disease

By Approach

  • Small Molecule Therapies
  • Single Strain Whole Bacteria
  • Microbial Consortia
  • Genetically Modified Single Strain Bacteria
  • Phage Cocktail
  • Microbial Ecosystems

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Human Microbiome Therapeutics Market By Product Type, By Therapeutic Area, By Indication, By Approach and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customisation offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Human Microbiome Therapeutics Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Product Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Human Microbiome Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Product Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Product Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Human Microbiome Therapeutics Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Probiotics
        2. Prebiotics
        3. Medical Foods
        4. Prescription Drugs

  • 8.   Global Human Microbiome Therapeutics Market, By Therapeutic Area Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Dental Disorders
        2. Autoimmune Disorders
        3. Digestive and Gastrointestinal Disorders
        4. Dermatological Disorders
        5. Infectious Disease
        6. Metabolic Disorders
        7. Oncology
        8. Others

  • 9.   Global Human Microbiome Therapeutics Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Acne Vulgaris
        2. Atopic Dermatitis
        3. Clostridium difficile Infection
        4. Colorectal Cancer
        5. Diabetes
        6. Inflammatory Bowel Disease (IBD)
        7. Lactose Intolerance
        8. Lung Cancer
        9. Non-alcoholic steatohepatitis (NASH)
        10. Obesity
        11. Coeliac Disease

  • 10.   Global Human Microbiome Therapeutics Market, By Approach Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Small Molecule Therapies
        2. Single Strain Whole Bacteria
        3. Microbial Consortia
        4. Genetically Modified Single Strain Bacteria
        5. Phage Cocktail
        6. Microbial Ecosystems

  • 11.   North America Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Human Microbiome Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Bristol-Myers Squibb Co.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Dow Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. ENTEROME SA
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Ferring Pharmaceuticals AS
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson and Johnson
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Kaleido Biosciences Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. PureTech Health Plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Second Genome Therapeutics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Seres Therapeutics Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Takeda Pharmaceutical Co. Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Vedanta Biosciences
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Whole Biome
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Naked Biome
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Evelo Biosciences
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. LNC Therapeutics
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Biotagenics
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Oxidien Pharmaceuticals, LLC
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. BoobyBiome
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. 4D Pharma PLC
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. UBiome
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Carbiotix
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. E.I. du Pont de Nemours and Company
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Finch Therapeutics
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. GNUbiotics Science
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. ClearB Therapeutics
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview
        26. GoodBelly
         26.1. Company Overview
         26.2. Product Portfolio
         26.3. SWOT Analysis
         26.4. Financial Overview
         26.5. Strategic Overview
        27. GoodGut
         27.1. Company Overview
         27.2. Product Portfolio
         27.3. SWOT Analysis
         27.4. Financial Overview
         27.5. Strategic Overview
        28. Synlogic
         28.1. Company Overview
         28.2. Product Portfolio
         28.3. SWOT Analysis
         28.4. Financial Overview
         28.5. Strategic Overview
        29. 16S Technologies
         29.1. Company Overview
         29.2. Product Portfolio
         29.3. SWOT Analysis
         29.4. Financial Overview
         29.5. Strategic Overview
        30. 5QBD-Biotech
         30.1. Company Overview
         30.2. Product Portfolio
         30.3. SWOT Analysis
         30.4. Financial Overview
         30.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11